286 related articles for article (PubMed ID: 23615756)
1. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.
Boonmuang P; Nathisuwan S; Chaiyakunapruk N; Suwankesawong W; Pokhagul P; Teerawattanapong N; Supsongserm P
Drug Saf; 2013 Sep; 36(9):779-87. PubMed ID: 23615756
[TBL] [Abstract][Full Text] [Related]
2. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.
Essers D; Schäublin M; Kullak-Ublick GA; Weiler S
Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215
[TBL] [Abstract][Full Text] [Related]
3. Statins and immune-mediated necrotizing myopathy: Variability in the risk.
Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B
Therapie; 2024; 79(3):365-370. PubMed ID: 37625939
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
5. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
[TBL] [Abstract][Full Text] [Related]
6. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study.
Settergren J; Eiermann B; Mannheimer B
PLoS One; 2013; 8(8):e69545. PubMed ID: 23940522
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
Montastruc JL
Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
9. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.
Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H
Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745
[TBL] [Abstract][Full Text] [Related]
10. Muscle rupture associated with statin use.
Ekhart C; de Jong L; Gross-Martirosyan L; van Hunsel F
Br J Clin Pharmacol; 2016 Aug; 82(2):473-7. PubMed ID: 27074553
[TBL] [Abstract][Full Text] [Related]
11. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Edwards IR; Star K; Kiuru A
Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
[TBL] [Abstract][Full Text] [Related]
12. Statin Associated Muscular Adverse Effects.
Kammoun R; Charfi O; Lakhoua G; Zaiem A; Daghfous R; Kastalli S; Aouinti I; Aidli SE
Curr Drug Saf; 2024; 19(1):114-116. PubMed ID: 36847228
[TBL] [Abstract][Full Text] [Related]
13. Statin safety: a systematic review.
Law M; Rudnicka AR
Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies.
Schwier NC; Cornelio CK; Boylan PM
Pharmacotherapy; 2022 Apr; 42(4):320-333. PubMed ID: 35175631
[TBL] [Abstract][Full Text] [Related]
15. Safety of herbal products in Thailand: an analysis of reports in the thai health product vigilance center database from 2000 to 2008.
Saokaew S; Suwankesawong W; Permsuwan U; Chaiyakunapruk N
Drug Saf; 2011 Apr; 34(4):339-50. PubMed ID: 21417506
[TBL] [Abstract][Full Text] [Related]
16. Statin safety: an assessment using an administrative claims database.
Cziraky MJ; Willey VJ; McKenney JM; Kamat SA; Fisher MD; Guyton JR; Jacobson TA; Davidson MH
Am J Cardiol; 2006 Apr; 97(8A):61C-68C. PubMed ID: 16581331
[TBL] [Abstract][Full Text] [Related]
17. Statin-associated ocular disorders: the FDA and ADRAC data.
Mizranita V; Pratisto EH
Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673
[TBL] [Abstract][Full Text] [Related]
18. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.
Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N
Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895
[TBL] [Abstract][Full Text] [Related]
19. Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai National Pharmacovigilance Database.
Win TS; Chaiyakunapruk N; Suwankesawong W; Dilokthornsakul P; Nathisuwan S
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):227-35. PubMed ID: 26342120
[TBL] [Abstract][Full Text] [Related]
20. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.
Molokhia M; McKeigue P; Curcin V; Majeed A
PLoS One; 2008 Jun; 3(6):e2522. PubMed ID: 18575628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
